Endoscopic and molecular characterization of colorectal sessile serrated adenoma/polyps with cytologic dysplasia

Gastrointestinal Endoscopy
Yoshihito TanakaHiroshi Nakase

Abstract

Sessile serrated adenoma/polyps (SSA/Ps), which are precursor lesions of colorectal cancer (CRC) with BRAF mutation and the CpG island methylator phenotype (CIMP), develop cytologic dysplasia (CD) during the progression of colorectal tumorigenesis. In the present study we aimed to clarify the endoscopic and molecular signatures of SSA/Ps, with and without CD. A series of 208 serrated lesions, including 41 hyperplastic polyps, 90 SSA/Ps, 33 SSA/Ps with CD, and 44 traditional serrated adenomas, were observed and resected using magnifying endoscopy. BRAF and KRAS mutations and methylation of CIMP markers (MINT1, MINT2, MINT12, MINT31, and p16) were analyzed through pyrosequencing. Molecular alterations were then compared with endoscopic and pathologic characteristics. Among SSA/Ps without CD, the Type II-Open pit pattern (Type II-O), BRAF mutation, and CIMP were tightly associated with a proximal colon location. SSA/Ps in the distal colon infrequently exhibited Type II-O and CIMP. By contrast, most SSA/Ps with CD showed Type II-O plus adenomatous pit patterns (Type III or IV), BRAF mutation, and CIMP, irrespective of their locations. Our results suggest that the Type II-O plus III/IV pit pattern is a common feature of SSA/Ps with ...Continue Reading

References

Jun 1, 1990·Cell·E R Fearon, B Vogelstein
Jul 1, 1996·Gastrointestinal Endoscopy·S KudoH Watanabe
Jul 21, 1999·Proceedings of the National Academy of Sciences of the United States of America·M ToyotaJ P Issa
Oct 1, 2008·Gastrointestinal Endoscopy·Shin ei KudoPaul D Hurlstone
Apr 28, 2010·Gastroenterology·Barbara Leggett, Vicki Whitehall
Jan 12, 2012·The American Journal of Gastroenterology·Tomoaki KimuraMinoru Toyota
Jun 20, 2012·The American Journal of Gastroenterology·Douglas K RexJames Church
Sep 13, 2012·World Journal of Gastroenterology : WJG·Shinya IshigookaFumio Itoh
Sep 22, 2012·The American Journal of Pathology·Eiichiro YamamotoMinoru Toyota
Jan 24, 2013·Histopathology·Mark BettingtonVicki Whitehall
Mar 30, 2013·Cancer Research·Andrea N Burnett-HartmanKaren W Makar
Feb 28, 2014·Endoscopy·Mariëlle W E BouwensSilvia Sanduleanu
Jun 4, 2014·Gastrointestinal Endoscopy·Nicholas G BurgessMichael J Bourke
Aug 16, 2014·The American Journal of Surgical Pathology·Homer O WilandRish K Pai
Sep 13, 2014·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Mark L BettingtonVicki Lj Whitehall

❮ Previous
Next ❯

Citations

Jan 30, 2018·Journal of Gastroenterology and Hepatology·Wataru SanoYasushi Sano
Jun 20, 2018·Histopathology·Hourin ChoShigeki Sekine
Mar 31, 2019·Postgraduate Medical Journal·Duochen JinBangmao Wang
Oct 1, 2019·Digestive Endoscopy : Official Journal of the Japan Gastroenterological Endoscopy Society·Shinji TanakaHisao Tajiri
Jun 26, 2020·Journal of Pathology and Translational Medicine·Jung Ho Kim, Gyeong Hoon Kang
Aug 7, 2018·Clinical Endoscopy·Eun Ran Kim, Dong Kyung Chang
Mar 17, 2018·Digestive Diseases and Sciences·Hironori AokiHiroshi Nakase
May 31, 2019·Surgical Endoscopy·Eduardo CoghlanAngel Nadales
Jun 2, 2020·World Journal of Gastroenterology : WJG·Wataru SanoYasushi Sano
Mar 13, 2021·Journal of Gastroenterology·Shinji TanakaKazuhiko Koike
Sep 21, 2021·American Journal of Clinical Pathology·Kenneth P BattsLawrence J Burgart

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.